Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)

NCT00040885 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

67

Enrollment

OTHER

Sponsor class

Conditions

Anorexia
Cachexia
Fatigue
Lung Cancer

Interventions

BIOLOGICAL: infliximab
DRUG: docetaxel
OTHER: placebo

Sponsor

Alliance for Clinical Trials in Oncology

Collaborators

[object Object]